Actavis (ACT) and Valeant Pharmaceuticals (VRX) resolve patent litigation related to the...

|By:, SA News Editor

Actavis (ACT) and Valeant Pharmaceuticals (VRX) resolve patent litigation related to the former's Abbreviated New Drug Applications for generic versions of Ziana and Zyclara which Actavis now agrees to launch in 2016 and 2019 respectively. Valeant will "receive a share of the economic benefits" from the marketing of the generics.